Surufatinib and serplulimab for advanced solid tumors with neuroendocrine features
Part of Cancer clinical trials.
This trial tests a combination of two drugs, surufatinib and serplulimab, for people with advanced solid tumors (like lung, stomach, or bowel cancer) that have stopped responding to standard treatments and have a specific cell change called neuroendocrine differentiation. The goal is to see if this new combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor (such as lung, stomach, bowel, breast, or prostate cancer) that has not responded well to standard treatments or you cannot tolerate them.
- Your tumor has a special feature called neuroendocrine differentiation, confirmed by a lab test.
- You are in good physical condition (ECOG score 0 or 1), meaning you can take care of yourself and are up and about.
- You have at least one tumor that can be measured on a CT scan.
- You have not had certain other cancer treatments within the last 4 weeks, and you haven't used surufatinib or serplulimab before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (surufatinib), immunotherapy (serplulimab), and standard chemotherapy as a first treatment for advanced solid tumors that have neuroendocrine features. It aims to see if this combination can shrink tumors and improve outcomes for patients with certain cancers.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
This trial tests a combination of two drugs (surufatinib and tislelizumab) for people with advanced lung cancer that has neuroendocrine markers. It may be an option if you haven't had certain prior treatments and your overall health is fairly good.
Hear when a new Advanced Solid Tumors With Neuroendocrine Differentiation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.